Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus

Cited by (2,856)

Items 301–400 of 2,856

1. Efficacy and Safety of Pemafibrate Versus Fenofibrate in Patients with High Triglyceride and Low HDL Cholesterol Levels: A Multicenter, Placebo-Controlled, Double-Blind, Randomized Trial
   Arai, Hidenori, Yamashita, Shizuya, Yokote, Koutaro, Araki, Eiichi, Suganami, Hideki, Ishibashi, Shun, on behalf of the K-877 Study Group · 2018 · Journal of Atherosclerosis and Thrombosis
2. Remnant cholesterol and myocardial infarction in normal weight, overweight, and obese individuals from the copenhagen general population study
   Varbo, Anette, Freiberg, Jacob J, Nordestgaard, Børge G · 2018 · Clinical Chemistry
3. Systematic Review for the 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines
   Peter W.F. Wilson, Tamar S. Polonsky, Michael D. Miedema, Amit Khera, Andrzej Stanislaw Kosinski, Jeffrey T. Kuvin · 2019 · Circulation
4. Advanced Glycation End Products, Oxidation Products, and Incident Cardiovascular Events in Patients With Type 2 Diabetes
   Koska, Juraj, Saremi, Aramesh, Howell, Scott, Bahn, Gideon, De Courten, Barbora, Ginsberg, Henry, Beisswenger, Paul J., Reaven, Peter D., for the VADT Investigators · 2018 · Diabetes Care
5. Lipid management in the prevention of stroke: a meta-analysis of fibrates for stroke prevention
   Yuhao Zhou, Xiaofei Ye, Feifei Yu, Xiao Zhang, Yingyi Qin, Jian Lu, Jia He · 2013 · BMC Neurology
6. Proof That Lower Is Better — LDL Cholesterol and IMPROVE-IT
   John Adams Jarcho, John F. Keaney · 2015 · New England Journal of Medicine
7. Evaluation of Time to Benefit of Statins for the Primary Prevention of Cardiovascular Events in Adults Aged 50 to 75 Years: A Meta-analysis
   Yourman, Lindsey C., Cenzer, Irena S., Boscardin, W. John, Nguyen, Brian T., Smith, Alexander K., Schonberg, Mara A., Schoenborn, Nancy L., Widera, Eric W., Orkaby, Ariela, Rodriguez, Annette et al. · 2021 · JAMA Internal Medicine
8. Lipolysis of triglyceride-rich lipoproteins, vascular inflammation, and atherosclerosis
   Schwartz, Eric A., Reaven, Peter D. · 2012 · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids
9. Role of Omega-3 Fatty Acids in Cardiovascular Disease: the Debate Continues
   Samuel C. R. Sherratt, Peter Libby, Matthew Jay Budoff, Deepak L. Bhatt, Richard Preston Mason · 2022 · Current Atherosclerosis Reports
10. Diabetes Mellitus and Cardiovascular Disease: Exploring Epidemiology, Pathophysiology, and Treatment Strategies
    Nawfal Hasan Siam, Nayla Nuren Snigdha, Noushin Tabasumma, Irin Parvin · 2024 · Reviews in Cardiovascular Medicine
11. Orthostatic Hypotension in the ACCORD (Action to Control Cardiovascular Risk in Diabetes) Blood Pressure Trial
    Jerome L. Fleg, Gregory W. Evans, Karen L. Margolis, Joshua I. Barzilay, Jan Basile, J. Thomas Bigger, Jeffrey A. Cutler, Richard H. Grimm, Carolyn F. Pedley, KEVIN A. PETERSON et al. · 2016 · Hypertension
12. New Insights into Mechanisms of Action for Omega-3 Fatty Acids in Atherothrombotic Cardiovascular Disease
    Preston Mason, R. · 2019 · Current Atherosclerosis Reports
13. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk
    Mach, François, Baigent, Colin, Catapano, Alberico L, Koskinas, Konstantinos C, Casula, Manuela, Badimon, Lina, Chapman, M John, De Backer, Guy G, Delgado, Victoria, Ference, Brian A et al. · 2020 · European Heart Journal
14. Efficacy and safety of K-877, a novel selective peroxisome proliferator-activated receptor α modulator (SPPARMα), in combination with statin treatment: Two randomised, double-blind, placebo-controlled clinical trials in patients with dyslipidaemia
    Arai, Hidenori, Yamashita, Shizuya, Yokote, Koutaro, Araki, Eiichi, Suganami, Hideki, Ishibashi, Shun · 2017 · Atherosclerosis
15. The evolution of domain arrangements in proteins and interaction networks
    Erich Bornberg‐Bauer, Francois Beaussart, Sarah Kummerfeld, Sarah Amalia Teichmann, January Mikolaj Weiner · 2005 · Cellular and Molecular Life Sciences
16. The Effect of Inflammation and Infection on Lipids and Lipoproteins
    Kenneth R. Feingold, Carl Grünfeld · 2015 · Europe PMC (PubMed Central)
17. Type 2 Diabetes
    Sandeep S. Vijan · 2015 · Annals of Internal Medicine
18. In Vivo Actions of Peroxisome Proliferator–Activated Receptors
    Roy Eldor, Ralph A. DeFronzo, Muhammad A Abdul‐Ghani · 2013 · Diabetes Care
19. Increased residual cardiovascular risk in patients with diabetes and high versus normal triglycerides despite statin‐controlled LDL cholesterol
    Nichols, Gregory A., Philip, Sephy, Reynolds, Kristi, Granowitz, Craig B., Fazio, Sergio · 2019 · Diabetes, Obesity and Metabolism
20. 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines
    Writing Committee Members, Blumenthal, Roger S., Morris, Pamela B., Gaudino, Mario, Johnson, Heather M., Anderson, Timothy S., Bittner, Vera A., Blankstein, Ron, Brewer, LaPrincess C., Cho, Leslie et al. · 2026 · Circulation
21. An Update on the Molecular Actions of Fenofibrate and Its Clinical Effects on Diabetic Retinopathy and Other Microvascular End Points in Patients With Diabetes
    Jonathan Edward Noonan, Alicia Josephine Jenkins, Jian‐xing Ma, ANTHONY C. KEECH, Jie Jin Wang, Ecosse Luc Lamoureux · 2013 · Diabetes
22. Post-transplant dyslipidemia: Mechanisms, diagnosis and management
    Arnav Agarwal, G. V. Ramesh Prasad · 2016 · World Journal of Transplantation
23. PPARs in the central nervous system: roles in neurodegeneration and neuroinflammation
    Juan Manuel Zolezzi, Manuel J. Santos, Sussy Bastias Candia, Claudio Pinto, Juan Alejandro Godoy, Nibaldo C. Inestrosa · 2017 · Biological reviews/Biological reviews of the Cambridge Philosophical Society
24. Management of diabetic dyslipidemia: An update
    Ishwarlal Jialal, Gurdeep Singh · 2019 · World Journal of Diabetes
25. Benefits and Safety of Long-Term Fenofibrate Therapy in People With Type 2 Diabetes and Renal Impairment
    Ting, Ru-Dee, Keech, Anthony C., Drury, Paul L., Donoghoe, Mark W., Hedley, John, Jenkins, Alicia J., Davis, Timothy M.E., Lehto, Seppo, Celermajer, David, Simes, R. John et al. · 2012 · Diabetes Care
26. Treatment of adults with Familial Hypercholesterolemia and evidence for treatment: Recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia
    Jennifer G. Robinson, Anne Carol Goldberg · 2011 · Journal of clinical lipidology
27. Longitudinal Patterns of Blood Pressure, Incident Cardiovascular Events, and All-Cause Mortality in Normotensive Diabetic People
    Zhijun Wu, Cheng Jin, Anand Vaidya, Wei Jin, Zhe Huang, Shouling Wu, Xiang Gao · 2016 · Hypertension
28. Diagnosis and treatment of apolipoprotein B dyslipoproteinemias
    Allan D. Sniderman, Patrick Couture, Jacqueline d Graaf · 2010 · Nature Reviews Endocrinology
29. Lipids and lipid management in diabetes
    Mamta Jaiswal, Ashley Schinske, Rodica Pop‐Busui · 2013 · Best Practice & Research Clinical Endocrinology & Metabolism
30. Effects of Intensive Systolic Blood Pressure Lowering on Cardiovascular Events and Mortality in Patients With Type 2 Diabetes Mellitus on Standard Glycemic Control and in Those Without Diabetes Mellitus: Reconciling Results From ACCORD BP and SPRINT
    Srinivasan Beddhu, Glenn Matthew Chertow, Tom Greene, Paul Kieran Whelton, Walter T. Ambrosius, Alfred K. Cheung, Jeffrey A. Cutler, Lawrence J. Fine, Robert E. Boucher, Guo Wei et al. · 2018 · Journal of the American Heart Association
31. Demystifying the management of hypertriglyceridaemia
    Watts, Gerald F., Ooi, Esther M. M., Chan, Dick C. · 2013 · Nature Reviews Cardiology
32. The association between triglycerides and incident cardiovascular disease: What is “optimal”?
    Tsion M. Aberra, Eric David Peterson, Neha Jadeja Pagidipati, Hillary S. Mulder, DANIEL M. WOJDYLA, Sephy Philip, Craig B. Granowitz, Ann Marie Návar · 2020 · Journal of clinical lipidology
33. The Role of Peroxisome Proliferator-Activated Receptor γ Coactivator 1α (PGC-1α) in Kidney Disease
    Szu‐Yuan Li, Katalin Suszták · 2018 · Seminars in Nephrology
34. Diabetes in Older People
    Graydon S. Meneilly, Aileen Knip, David B. Miller, Diana Sherifali, Daniel Tessier, Afshan Zahedi · 2018 · Canadian Journal of Diabetes
35. High Triglycerides Are Associated With Increased Cardiovascular Events, Medical Costs, and Resource Use: A Real‐World Administrative Claims Analysis of Statin‐Treated Patients With High Residual Cardiovascular Risk
    Toth, Peter P., Granowitz, Craig, Hull, Michael, Liassou, Djibril, Anderson, Amy, Philip, Sephy · 2018 · Journal of the American Heart Association
36. Pharmacological strategies for lowering LDL cholesterol: statins and beyond
    Ariel Brautbar, Christie Mitchell Ballantyne · 2011 · Nature Reviews Cardiology
37. American Association of Clinical Endocrinologists’ Guidelines for Management of Dyslipidemia and Prevention of Atherosclerosis: Executive Summary
    Paul S. Jellinger, Donald Angehr Smith, Adi Mehta, Om P. Ganda, Yehuda Handelsman, Helena W. Rodbard, Mark D. Shepherd, John A. Seibel, Robert A. Kreisberg, Ronald B Goldberg · 2012 · Endocrine Practice
38. CER-001, a HDL-mimetic, stimulates the reverse lipid transport and atherosclerosis regression in high cholesterol diet-fed LDL-receptor deficient mice
    Claudine Tardy, Marine Goffinet, Nadia Boubekeur, Rose Ackermann, Gavin Sy, Alice Bluteau, Guy Cholez, Constance Keyserling, Narendra D. Lalwani, John F. Paolini et al. · 2013 · Atherosclerosis
39. Pharmacological management of nonalcoholic fatty liver disease
    Barb, Diana, Portillo-Sanchez, Paola, Cusi, Kenneth · 2016 · Metabolism
40. Bilirubin, a Cardiometabolic Signaling Molecule
    Terry D. Hinds, David E. Stec · 2018 · Hypertension
41. Therapeutic Potential of Copper Chelation with Triethylenetetramine in Managing Diabetes Mellitus and Alzheimerʼs Disease
    Garth J. S. Cooper · 2011 · Drugs
42. The pharmacological management of metabolic syndrome
    Julie Rask Larsen, Lorena Dima, Christoph Ulrich Correll, Peter Manu · 2018 · Expert Review of Clinical Pharmacology
43. Diabetes and Cardiovascular Disease: an Update
    Almourani, Rajaa, Chinnakotla, Bhavana, Patel, Richa, Kurukulasuriya, L. Romayne, Sowers, James · 2019 · Current Diabetes Reports
44. Efficacy and tolerability of adding coenzyme A 400 U/d capsule to stable statin therapy for the treatment of patients with mixed dyslipidemia: an 8-week, multicenter, double-Blind, randomized, placebo-controlled study
    Jiangtao Lai, Bifeng Wu, Tianming Xuan, Zhong Liu, Jun-zhu Chen · 2014 · Lipids in Health and Disease
45. Cardiovascular disease and glycemic control in type 2 diabetes: now that the dust is settling from large clinical trials
    Francesco Giorgino, Anna Leonardini, Luigi Laviola · 2013 · Annals of the New York Academy of Sciences
46. Glucose targets for preventing diabetic kidney disease and its progression
    Ruospo, Marinella, Saglimbene, Valeria M, Palmer, Suetonia C, De Cosmo, Salvatore, Pacilli, Antonio, Lamacchia, Olga, Cignarelli, Mauro, Fioretto, Paola, Vecchio, Mariacristina, Craig, Jonathan C et al. · 2017 · Cochrane Database of Systematic Reviews
47. Effects of free omega-3 carboxylic acids and fenofibrate on liver fat content in patients with hypertriglyceridemia and non-alcoholic fatty liver disease: A double-blind, randomized, placebo-controlled study
    Jan Oscarsson, Kristina Önnerhag, Ulf Risérus, Mattias Sundén, Lars Johansson, Per‐Anders Jansson, Linda Moris, Peter M. Nilsson, Jan W. Eriksson, Lars Lind · 2018 · Journal of clinical lipidology
48. Glycogen Synthase Kinase-3α Promotes Fatty Acid Uptake and Lipotoxic Cardiomyopathy
    Michinari Nakamura, Tong Liu, Seema Husain, Peiyong Zhai, Junco S. Warren, Chiao‐Po Hsu, Takahisa Matsuda, Christopher J. Phiel, James Eric Cox, Bin Tian et al. · 2019 · Cell Metabolism
49. Circulating Selenium and Prostate Cancer Risk: A Mendelian Randomization Analysis
    James Yarmolinsky, Carolina Bonilla, Philip Haycock, Ryan Langdon, Luca Andrea Lotta, Claudia Langenberg, Caroline L. Relton, Sarah Jane Lewis, David M. Evans, George Davey Smith et al. · 2018 · JNCI Journal of the National Cancer Institute
50. The Diagnosis and Treatment of Hypertriglyceridemia
    Parhofer, Klaus G., Laufs, Ulrich · 2019 · Deutsches Ärzteblatt international
51. Association of Air Pollution Exposures With High-Density Lipoprotein Cholesterol and Particle Number
    Griffith A. Bell, Samia Mora, Philip Greenland, Michael Y. Tsai, Ed Gill, Joel D. Kaufman · 2017 · Arteriosclerosis Thrombosis and Vascular Biology
52. HDL Triglycerides: A New Marker of Metabolic and Cardiovascular Risk
    Josefa Girona, Núria Amigó, Daiana Ibarretxe, Núria Plana, Cèlia Rodríguez-Borjabad, Mercedes Heras, Raimón Ferré, Míriam Gil, Xavier Correig, L. Masana · 2019 · International Journal of Molecular Sciences
53. The Role of Lipids and Lipoproteins in Atherosclerosis
    MacRae F. Linton, Patricia G. Yancey, Sean S. Davies, W. Gray Jerome, Edward F. Linton, Wen‐Liang Song, Amanda C. Doran, Kasey C. Vickers · 2015 · Europe PMC (PubMed Central)
54. Triglyceride-Rich Lipoprotein Remnants and Cardiovascular Disease
    Edward K. Duran, Aruna D. Pradhan · 2020 · Clinical Chemistry
55. Overview of omega-3 Fatty Acid therapies.
    J. Chris Bradberry, Daniel E. Hilleman · 2013 · PubMed Central
56. Sex-Specific differences in metabolic control, cardiovascular risk, and interventions in patients with type 2 diabetes mellitus
    Alexandra Kautzky‐Willer, Majid Reza Kamyar, Dora Gerhat, Ammon Handisurya, Gunar Stemer, Stephen S. Hudson, Anton Luger, Rosa Lemmens‐Gruber · 2010 · Gender Medicine
57. Treating NASH by targeting peroxisome proliferator-activated receptors
    Bart Staels, Laura Butruille, Sven Francque · 2023 · Journal of Hepatology
58. 2023 China Guidelines for Lipid Management
    Jian‐Jun Li, Shui‐Ping Zhao, Dong Zhao, Guoping Lü, Daoquan Peng, Jing Liu, Zhen‐Yue Chen, Yuan‐Lin Guo, Na‐Qiong Wu, Sheng-kai Yan et al. · 2023 · 老年心脏病学杂志：英文版
59. Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention
    Michaeli, Daniel Tobias, Michaeli, Julia Caroline, Albers, Sebastian, Boch, Tobias, Michaeli, Thomas · 2023 · American Journal of Cardiovascular Drugs
60. The key role of altered tubule cell lipid metabolism in kidney disease development
    Lauren E. Lee, Tomohito Doke, Dhanunjay Mukhi, Katalin Suszták · 2024 · Kidney International
61. 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026
    American Diabetes Association Professional Practice Committee for Diabetes*, Bajaj, Mandeep, McCoy, Rozalina G., Balapattabi, Kirthikaa, Bannuru, Raveendhara R., Bellini, Natalie J., Bennett, Allison K., Beverly, Elizabeth A., Briggs Early, Kathaleen, ChallaSivaKanaka, Sathyavathi et al. · 2026 · Diabetes Care
62. Atherogenic Dyslipidemia and Residual Cardiovascular Risk in Statin-Treated Patients
    Gaia Sirimarco, Julien Labreuche, Éric Bruckert, Larry B. Goldstein, Kim Michael Fox, Peter Malcolm Rothwell, Pierre Amarenco, Marie‐Germaine Bousser, Ángel Chamorro, Ian Ford et al. · 2014 · Stroke
63. Triglycerides and risk of atherosclerotic cardiovascular disease: An update
    Michel Farnier, Marianne Zeller, David Masson, Yves Cottin · 2021 · Archives of cardiovascular diseases
64. 2024 Clinical practice guidelines for Stable coronary artery disease
    О. Л. Барбараш, Yu. A. Karpov, A. V. Panov, Renat S. Akchurin, Bagrat G. Alekyan, Mikhail N. Alekhin, D. M. Aronov, GOHAR HARUTYUNYAN, Yu. N. Belenkov, Sergey Anatol'evich Boytsov et al. · 2024 · Russian Journal of Cardiology
65. Activation of PPAR-α in the early stage of heart failure maintained myocardial function and energetics in pressure-overload heart failure
    Kaimoto, Satoshi, Hoshino, Atsushi, Ariyoshi, Makoto, Okawa, Yoshifumi, Tateishi, Shuhei, Ono, Kazunori, Uchihashi, Motoki, Fukai, Kuniyoshi, Iwai-Kanai, Eri, Matoba, Satoaki · 2017 · American Journal of Physiology-Heart and Circulatory Physiology
66. A VOYAGER Meta-Analysis of the Impact of Statin Therapy on Low-Density Lipoprotein Cholesterol and Triglyceride Levels in Patients With Hypertriglyceridemia
    Karlson, Björn W., Palmer, Michael K., Nicholls, Stephen J., Lundman, Pia, Barter, Philip J. · 2016 · The American Journal of Cardiology
67. Sex and gender differences in therapy of type 2 diabetes
    Alexandra Kautzky‐Willer, Jürgen Harreiter · 2017 · Diabetes Research and Clinical Practice
68. National Lipid Association Scientific Statement on the use of icosapent ethyl in statin-treated patients with elevated triglycerides and high or very-high ASCVD risk
    Orringer, Carl E., Jacobson, Terry A., Maki, Kevin C. · 2019 · Journal of Clinical Lipidology
69. Dyslipidemia in women: etiology and management
    Peter Paul Toth, Binh An P. Phan · 2014 · International Journal of Women s Health
70. Alirocumab vs usual lipid‐lowering care as add‐on to statin therapy in individuals with type 2 diabetes and mixed dyslipidaemia: The ODYSSEY DM‐DYSLIPIDEMIA randomized trial
    Kausik Kumar Ray, Lawrence A. Leiter, Dirk Müller‐Wieland, Bertrand Cariou, Helen Martina Colhoun, Robert R. Henry, Francisco José Tinahones, Maja Bujas‐Bobanovic, Catherine Domenger, Alexia Letierce et al. · 2018 · Diabetes Obesity and Metabolism
71. Increased Cardiovascular Risk in Hypertriglyceridemic Patients With Statin-Controlled LDL Cholesterol
    Nichols, Gregory A, Philip, Sephy, Reynolds, Kristi, Granowitz, Craig B, Fazio, Sergio · 2018 · The Journal of Clinical Endocrinology & Metabolism
72. High-Density Lipoprotein Maintains Skeletal Muscle Function by Modulating Cellular Respiration in Mice
    M. Lehti, Elizabeth M. Donelan, William Abplanalp, O. Al-Massadi, K. Habegger, J. Weber, Chandler Ress, Johannes Mansfeld, S. Somvanshi, Chitrang J. Trivedi et al. · 2013 · Circulation
73. Ability of traditional lipid ratios and apolipoprotein ratios to predict cardiovascular risk in people with type 2 diabetes
    on behalf of the FIELD study investigators, Taskinen, M.-R., Barter, P. J., Ehnholm, C., Sullivan, D. R., Mann, K., Simes, J., Best, J. D., Hamwood, S., Keech, A. C. · 2010 · Diabetologia
74. Fenofibrate – A Potential Systemic Treatment for Diabetic Retinopathy?
    Tien Yin Wong, Rafael Simó, Paul L.R. Mitchell · 2012 · American Journal of Ophthalmology
75. Diabetic Retinopathy Preferred Practice Pattern®
    Jennifer I. Lim, Stephen Jae Kim, Steven T. Bailey, Jaclyn Lekse Kovach, G. Atma Vemulakonda, Gui‐Shuang Ying, Christina J. Flaxel · 2025 · Ophthalmology
76. Stroke and diabetes mellitus
    Michael D. Hill · 2014 · Handbook of clinical neurology
77. New therapeutic principles in dyslipidaemia: focus on LDL and Lp(a) lowering drugs
    Norata, Giuseppe Danilo, Ballantyne, Christie M., Catapano, Alberico Luigi · 2013 · European Heart Journal
78. Adipose tissue dysfunction and hypertriglyceridemia: mechanisms and management
    Anton P. van de Woestijne, Houshang Monajemi, Eric Kalkhoven, Frank L.J. Visseren · 2011 · Obesity Reviews
79. Insulin and glucose-lowering agents for treating people with diabetes and chronic kidney disease
    Clement Lo, Tadashi Toyama, Ying Wang, Jin Lin, Yoichiro Hirakawa, Min Jun, Alan Cass, Carmel Mary Hawley, Helen Pilmore, Sunil V. Badve et al. · 2018 · Cochrane Database of Systematic Reviews
80. Cardiovascular Disease and Risk Management: Review of the American Diabetes Association Standards of Medical Care in Diabetes 2018
    James J. Chamberlain, Eric L. Johnson, Sandra Leal, Andrew S. Rhinehart, Jay H. Shubrook, Lacie Peterson · 2018 · Annals of Internal Medicine
81. Triglycerides and atherogenic dyslipidaemia: Extending treatment beyond statins in the high-risk cardiovascular patient
    Watts, Gerald F, Karpe, Fredrik · 2011 · Heart
82. Current practice in identifying and treating cardiovascular risk, with a focus on residual risk associated with atherogenic dyslipidaemia
    Roberto Ferrari, Carlos Aguíar, Eduardo Alegría, Riccardo C. Bonadonna, Francesco Cosentino, Moses Elisaf, Michel Farnier, Jean Ferrières, Pasquale Perrone Filardi, Nicolae Hâncu et al. · 2016 · European Heart Journal Supplements
83. Current Data Regarding the Relationship between Type 2 Diabetes Mellitus and Cardiovascular Risk Factors
    Cosmin Mihai Vesa, Loredana Popa, Amorin Remus Popa, Marius Rus, Andreea Atena Zaha, SIMONA GABRIELA BUNGAU, Delia Mirela Ţiţ, Raluca Anca Corb Aron, Dana Carmen Zaha · 2020 · Diagnostics
84. Lipid Abnormalities in Patients with Chronic Kidney Disease: Implications for the Pathophysiology of Atherosclerosis
    William F. Keane, Joanne E. Tomassini, David Neff · 2012 · Journal of Atherosclerosis and Thrombosis
85. Persistent lipid abnormalities in statin‐treated patients with diabetes mellitus in Europe and Canada: results of the Dyslipidaemia International Study
    Lawrence A. Leiter, Pia Lundman, P. M. da Silva, Heinz Drexel, Claus Jünger, Anselm Kai Gitt, on behalf of the DYSIS investigators · 2011 · Diabetic Medicine
86. Beginning to Understand High-Density Lipoproteins
    Carlos G. Santos‐Gallego, Juan J. Badimon, Robert S. Rosenson · 2014 · Endocrinology and Metabolism Clinics of North America
87. Dyslipidemia in diabetic nephropathy
    Daiji Kawanami, Keiichiro Matoba, Kazunori Utsunomiya · 2016 · Renal Replacement Therapy
88. Role of Niacin in Current Clinical Practice: A Systematic Review
    Aakash Garg, Abhishek Sharma, Parasuram Melarcode Krishnamoorthy, Jalaj Garg, Deepti Virmani, Toishi Sharma, Giulio Giuseppe Stefanini, John B. Kostis, Debabrata Mukherjee, Ekaterina Sikorskaya · 2016 · The American Journal of Medicine
89. Fibrates Revisited: Potential Role in Cardiovascular Risk Reduction
    Nam Hoon Kim, Sin Gon Kim · 2020 · Diabetes & Metabolism Journal
90. Evaluating cardiovascular event reduction with ezetimibe as an adjunct to simvastatin in 18,144 patients after acute coronary syndromes: Final baseline characteristics of the IMPROVE-IT study population
    Michael A. Blazing, Robert Patrick Giugliano, Christopher Paul Cannon, Thomas A. Musliner, Andrew M. Tershakovec, Jennifer A. White, Craig Reist, Amy McCagg, Eugene Braunwald, Robert M. Califf · 2014 · American Heart Journal
91. Atherogenic index of plasma is an effective index for estimating abdominal obesity
    Shiwei Shen, Yun Lu, Feng Li, Chengjian Yang, Yin-Bo Feng, Hongwei Li, Weifeng Yao, Zhenhai Shen · 2018 · Lipids in Health and Disease
92. Dysfunctional high-density lipoproteins in coronary heart disease: implications for diagnostics and therapy
    Annema, Wijtske, von Eckardstein, Arnold · 2016 · Translational Research
93. Validation of Risk Equations for Complications of Type 2 Diabetes (RECODe) Using Individual Participant Data From Diverse Longitudinal Cohorts in the U.S.
    Sanjay Basu, Jeremy B. Sussman, Seth A. Berkowitz, Rodney A. Hayward, Alain Gerald Bertoni, Adolfo Correa, Stanford E. Mwasongwe, John S Yudkin · 2017 · Diabetes Care
94. Use of fenofibrate on cardiovascular outcomes in statin users with metabolic syndrome: propensity matched cohort study
    Nam Hoon Kim, Ki Hoon Han, Jimi Choi, Juneyoung Lee, Sin Gon Kim · 2019 · BMJ
95. Aggressive LDL-C Lowering and the Brain: Impact on Risk for Dementia and Hemorrhagic Stroke: A Scientific Statement From the American Heart Association
    Larry B. Goldstein, Peter Paul Toth, Jennifer L. Dearborn, Robert Patrick Giugliano, Benjamin J. Hirsh, Jessica M. Peña, Magdy H. Selim, Daniel Woo · 2023 · Arteriosclerosis Thrombosis and Vascular Biology
96. Effect of Fenofibrate on Progression of Diabetic Retinopathy
    David Preiss, Jennifer Logue, Emily L. Sammons, Mohammed Zayed, Jonathan Emberson, Rachel L. Wade, Karl Wallendszus, Will Stevens, Rosanna Cretney, Simon Peter Harding et al. · 2024 · NEJM Evidence
97. Hypertriglyceridemia and cardiovascular risk: a cautionary note about metabolic confounding
    Allan D. Sniderman, Patrick Couture, Seth Shay Martin, J DEGRAAF, Patrick R. Lawler, William C. Cromwell, John T. Wilkins, George Thanassoulis · 2018 · Journal of Lipid Research
98. Peroxisome Proliferator-Activated Receptors and the Heart: Lessons from the Past and Future Directions
    Wang Soo Lee, Jaetaek Kim · 2015 · PPAR Research
99. Comparison of the effects of fibrates versus statins on plasma lipoprotein(a) concentrations: a systematic review and meta-analysis of head-to-head randomized controlled trials
    Amirhossein Sahebkar, Luis E. Simental‐Mendía, Gerald Francis Watts, Maria-Corina Șerban, Maciej Banach · 2017 · BMC Medicine
100. Effect of Intensive Blood Pressure Lowering on Left Ventricular Hypertrophy in Patients With Diabetes Mellitus
     Elsayed Z. Soliman, Robert P. Byington, J. Thomas Bigger, Gregory W. Evans, Peter M. Okin, David Calvin Goff, Haiying Chen · 2015 · Hypertension